A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients With Phlebotomy Dependent Polycythemia Vera (PD-PV)
Latest Information Update: 05 Jan 2026
At a glance
- Drugs Sapablursen (Primary)
- Indications Polycythaemia vera
- Focus Therapeutic Use
- Acronyms IMPRSSION
- Sponsors Ionis Pharmaceuticals
Most Recent Events
- 08 Dec 2025 According to an Deciphera Pharmaceuticals media release, data from this trial were presented at the 67th American Society of Hematology (ASH) Annual Meeting.
- 08 Dec 2025 Results presented in the Ono Pharmaceutical Media Release.
- 06 Dec 2025 Primary endpoint has been met. (Change in the frequency of phlebotomy comparing Baseline with the last 20 weeks of the 37 week Treatment Period)